The Allergy Therapeutics plc (LON: AGY) share price was trading flat for the day despite the company announcing that it had completed dosing healthy volunteers within the first two cohorts of its Phase I PROTECT trial. The trial is testing the firm’s novel virus-like particle (VLP)-based peanut allergy vaccine candidate.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.
The company noted that the external safety review committee (SRC) had approved the dosing of the successive cohorts. Furthermore, the SRC approved the beginning of subcutaneous dose escalation in peanut-allergic subjects following the completion of the skin-prick testing phase in April 2023.
Searching for the Perfect Broker?
Discover our top-recommended brokers for trading stocks, forex, cryptos, and beyond. Dive in and test their capabilities with complimentary demo accounts today!
- eToro Top stock trading platform with 0% commission – Read our Review
- Admiral Markets More than 4500 stocks & over 200 ETFs available to invest in – Read our Review
- BlackBull 26,000+ Shares, Options, ETFs, Bonds, and other underlying assets – Read our Review
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY
The subcutaneous dose escalation in peanut-allergic participants marks the beginning of the early proof of concept phase of the PROTECT trial. The company expects to begin this critical stage of the PROTECT trial soon. The trial’s full results are expected in 2024.
The trial is being conducted in peanut-allergic patients and healthy volunteers and is split into two parts. Part A is an open-label study of four groups (cohorts) of healthy participants (Group A1) who will be dosed subcutaneously in ascending dose concentrations of VLP peanut.
The second group (Group A2) of peanut-allergic patients had undergone skin prick tests conducted with rising concentrations of the vaccine candidate (completed in April 2023).
Part B is a double-blind, placebo-controlled trial enrolling peanut-allergic patients who will receive rising doses of the vaccine candidate injected subcutaneously. The PROTECT trial builds on the findings from the VLP001 study conducted at the Imperial College London.
Manuel Llobet, Chief Executive Officer of Allergy Therapeutics, commented: “We welcome the positive progress in our PROTECT trial and are pleased with the safety review committee's approval to begin multiple subcutaneous dosing of peanut-allergic patients in the final phase of the trial.”
“Peanut allergy is one of the most common types of food allergies. For some people, even the smallest amounts of peanuts can cause a potentially life-threatening reaction. A safe and effective short-course vaccine that provides long-term protection and a long-lasting protective immune response can bring a paradigm shift in treating peanut allergy, changing the lives of those living with the allergy.”
Allergy Therapeutics (AGY) share price.
The Allergy Therapeutics (AGY) share price was trading flat for the day despite today’s announcement.
YOUR CAPITAL IS AT RISK. 76% OF RETAIL CFD ACCOUNTS LOSE MONEY.